Gefitinib’s reversible suppression of EGFR mutant tumors has gained global approval since its first in-human dosing in 1998, but acquired resistance ultimately occurs, and this has become a major restriction in advanced NSCLC [26]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.